NCT06772090 is a NA clinical trial of Lactobacillus and Bifidobacterium in Solid Tumor, Adult, sponsored by Masonic Cancer Center, University of Minnesota.

Who is sponsoring NCT06772090?

NCT06772090 is sponsored by Masonic Cancer Center, University of Minnesota.

What drugs are being tested in NCT06772090?

Interventions in NCT06772090: Lactobacillus and Bifidobacterium, Placebo.

What condition does NCT06772090 study?

NCT06772090 studies Solid Tumor, Adult, Cytotoxicity.

Is NCT06772090 still recruiting?

NCT06772090 is currently not yet recruiting. Last updated 3 February 2026.

Last reviewed 2026-02-03 · How we verify

NCT06772090

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies

Not yet recruiting NA Last updated 3 February 2026

What this trial tests

NA trial testing Lactobacillus and Bifidobacterium in Solid Tumor, Adult in 40 participants. Not yet recruiting.

Timeline

25 December 2026

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Masonic Cancer Center, University of Minnesota
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	40
Start date	25 December 2026
Primary completion	31 December 2027
Estimated completion	31 December 2028

Drugs / interventions tested

Lactobacillus and Bifidobacterium — full drug profile →
Placebo

Conditions studied

Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Cytotoxicity — all drugs for Cytotoxicity →

Sponsor

Masonic Cancer Center, University of Minnesota

Who can join

18 and older, any sex, with Solid Tumor, Adult or Cytotoxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot single-blind placebo-controlled randomized trial to establish experimental feasibility. We plan on enrolling a pilot cohort of 40 patients, with up to 5 patients in treatment phase 0 and the remaining in treatment phase I. During Phase I, the remaining participants will be assigned to either treatment or control group using dynamic block randomization balancing on sex, age group, and disease histology.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Engineered <i>Bifidobacterium</i> Strains Colonization at Tumor Sites: A Novel Approach to the Delivery of Cancer Treatments.
Amonkar R, Uy AA, Ramirez P, Patel H, et al · · 2025 · cited 4× · PMID 40805186 · DOI 10.3390/cancers17152487
Gut microbiota drives cancer evolution and therapy resistance.
Min S, Zhang Y, Zhang H, Liu Q. · · 2026 · PMID 41527087 · DOI 10.1186/s12943-025-02564-8

Verify or expand the search:

Other recruiting trials for Solid Tumor, Adult

Currently open trials in the same condition.

NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting

Other Masonic Cancer Center, University of Minnesota trials

Trials by the same sponsor.

NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting
NCT07008638 — Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53- · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06772090 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 3 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06772090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing